Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

Abstract Background Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5) receptor (IL-5R), was used before marketing authorisation in Spain in a real world setting as part of an early-access programme (EAP) to treat patients with severe eosinophilic asthma with prior insuffic...

Full description

Bibliographic Details
Main Authors: Eva Martínez-Moragón, Ismael García-Moguel, Javier Nuevo, Gustavo Resler, ORBE study investigators
Format: Article
Language:English
Published: BMC 2021-12-01
Series:BMC Pulmonary Medicine
Subjects:
Asthma
Severe asthma
Eosinophilic asthma
Benralizumab
Biological treatment
Early access programme
Online Access:https://doi.org/10.1186/s12890-021-01785-z

Internet

https://doi.org/10.1186/s12890-021-01785-z

Similar Items